“In vitro” hyperosmolar design in human corneal epithelial cells and inflammation in macrophages: avoiding the use of animals in the screening of ocular surface therapies
-
López Cano, JJ [1] [2] ; González Cela-Casamayor, MA [1] [2] ; Andrés Guerrero, V [1] [2] ; Benítez Del Castillo, JM [2] [2] ; Herrero Vanrel, Rocío [1] [2] ; Molina Martínez, I [1] [2]
-
[1] Universidad Complutense de Madrid
Universidad Complutense de Madrid
Madrid, España
-
[2] Hospital Clínico San Carlos de Madrid
Hospital Clínico San Carlos de Madrid
Madrid, España
-
- Localización: RESCIFAR Revista Española de Ciencias Farmacéuticas, ISSN-e 2660-6356, Vol. 2, Nº. 2, 2021 (Ejemplar dedicado a: XV CONGRESO DE LA SOCIEDAD ESPAÑOLA DE FARMACIA INDUSTRIA Y GALÉNICA), págs. 41-43
- Idioma: inglés
- Enlaces
-
Resumen
Keratoconjunctivitis sicca (SS-KCS) is a pathology affecting the ocular surface and tear film stability]. When a hypertonic environment occurs, specific biochemical pathways are activated leading to apoptosis. Substances protecting cells against hyperosmolarity by stabilization of cell´s membrane through their accumulation are commonly described as osmoprotectants. There are substances employed for the treatment of SS-KCS with anti-inflammatory properties. L-Carnitine, Taurine or Betaine are known to possess osmoprotective properties and the mucoadhesive polymer hyaluronic acid (HA) has demonstrated to have anti-inflammatory effect. Commonly, the use of animals is considered for ocular drug screening, however following the principle of replacement, reduction, and refinement (3Rs), alternative in vitro models should be developed. The aim of the present study is to simulate in vitro hyperosmolar and inflammatory conditions for fast screening of ocular therapies avoiding the use of animals following the 3Rs principle.
